About Agenovir
Agenovir is a company based in San Francisco (United States) founded in 2014 was acquired by Vir Biotechnology in May 2018.. Agenovir has raised $10.6 million across 2 funding rounds from investors including Lightspeed Venture Partners, Vir Biotechnology and HHS. Agenovir operates in a competitive market with competitors including Moderna, BridgeBio, Adaptive Biotechnologies, Spark Therapeutics and Alnylam, among others.
- Headquarter San Francisco, United States
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
- Legal Name Agenovir Corporation
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$10.6 M (USD)
in 2 rounds
-
Latest Funding Round
$10.6 M (USD), Series A
May 17, 2016
-
Investors
Lightspeed Venture Partners
& 4 more
-
Employee Count
Employee Count
-
Acquired by
Vir Biotechnology
(May 10, 2018)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Leadership Team
45 people
Operations Team
11 people
Software Development Team
8 people
Senior Team
8 people
Finance and Accounting
6 people
Product Management Team
3 people
Human Resources and Administration
2 people
Sales and Marketing
2 people
Unlock access to complete
Funding Insights of Agenovir
Agenovir has successfully raised a total of $10.6M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $10.6 million completed in May 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series A — $10.6M
-
First Round
First Round
(01 Jan 2016)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2016 | Amount | Series A - Agenovir | Valuation |
investors |
|
| Jan, 2016 | Amount | Grant - Agenovir | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Agenovir
Agenovir has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Lightspeed Venture Partners, Vir Biotechnology and HHS. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on multiple sectors
|
Founded Year | Domain | Location | |
|
Venture capital investing in innovative companies across global sectors is undertaken by Lightspeed Venture Partners.
|
Founded Year | Domain | Location | |
|
Therapies for cancer and inflammatory diseases are developed.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Agenovir
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Agenovir
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Agenovir Comparisons
Competitors of Agenovir
Agenovir operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Adaptive Biotechnologies, Spark Therapeutics and Alnylam, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Agenovir
When was Agenovir founded?
Agenovir was founded in 2014 and raised its 1st funding round 2 years after it was founded.
Where is Agenovir located?
Agenovir is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Is Agenovir a funded company?
Agenovir is a funded company, having raised a total of $10.6M across 2 funding rounds to date. The company's 1st funding round was a Grant of $136.77K, raised on Jan 01, 2016.
What does Agenovir do?
Agenovir was established in 2014 in San Francisco, United States, within the biotechnology sector. Focus is placed on creating antiviral therapeutics targeting infectious diseases tied to latent or persistent viral reservoirs. CRISPR-Cas9 and other nucleases are employed to target and remove pathogenic viral DNA inside cells. Development efforts center on innovative gene-editing methods to address viral persistence.
Who are the top competitors of Agenovir?
Agenovir's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Who are Agenovir's investors?
Agenovir has 5 investors. Key investors include Lightspeed Venture Partners, Vir Biotechnology, HHS, Celgene, and DCVC.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.